| Neulasta (pegfilgrastim) / Roche |
NCT00113789: Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer |
|
|
| Completed | 2 | 21 | US | PI Discretion | Amgen | Ovarian Cancer | 04/05 | 04/05 | | |
NCT00217568: Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer |
|
|
| Completed | 2 | | US | pegfilgrastim, carboplatin, docetaxel | Fred Hutchinson Cancer Center, National Cancer Institute (NCI) | Ovarian Cancer, Peritoneal Cavity Cancer | 03/06 | | | |
NCT02469116: Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma |
|
|
| Terminated | 2 | 18 | US | Docetaxel, Docefrez®, Taxotere®, Carboplatin, Paraplatin, CBDCA, Pegylated G-CSF, Neulasta®), Pegfilgrastim | Washington University School of Medicine, Sanofi | Ovarian Cancer | 08/09 | 03/10 | | |
NCT00569673: Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer |
|
|
| Completed | 2 | 71 | US | filgrastim, pegfilgrastim, docetaxel, trabectedin | Gynecologic Oncology Group, National Cancer Institute (NCI) | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | 01/12 | | | |
NCT00217529: Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer |
|
|
| Completed | 1/2 | | US | pegfilgrastim, carboplatin, docetaxel, erlotinib hydrochloride | Fred Hutchinson Cancer Center | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer | 11/05 | | | |
